women and in children under 5 years of age. However, long-term prophylaxis by vaccination has been especially challenging as the parasite has various sophisticated mechanisms to avoid the host immune system. Currently, no vaccine is available. The most effective first-generation vaccine in development, GlaxoSmithKline (GSK)'s RTSS, reduces the risk of clinical malaria, delays time to new infection and reduces episodes of severe malaria for at least 18 months 4 . It has recently entered Phase III clinical trials. Even with all available strategies combined, gaps remain in our armoury against malaria, and a substantial number of patients will suffer from this disease over the coming decades.
In November 2007, the Bill and Melinda Gates Foundation set an agenda with the final goal of the eradication of malaria (that is, the extinction of all species of Plasmodium that can cause malaria in humans) 5 . This goal is also supported by the World Health Organization (WHO) through its Roll Back Malaria (RBM) partnership (see Further information), by the Global Fund to Fight AIDS, Tuberculosis and Malaria (see Further information), a related developing initiative -the Affordable Medicines Facility for malaria (AMFm)and the Malaria Eradication Research Agenda (MalERA; see Further information). To achieve the goal of eradication, antimalarial drug discovery must continue working on the development of new medicines to treat malaria *Medicines for Malaria Venture, 20 Route de Pré-Bois, 1215 Geneva, Switzerland.
Artemisinin-based combination therapy (ACT) . A treatment regimen for malaria, usually comprising two medicines, one of which is artemisinin or one of its derivatives. ACTs come in two varieties: co-packaged or the preferred co-formulated.
Merozoite
The life cycle stage in which the malaria parasite has the ability to penetrate and infect red blood cells. The parasite expresses receptors and proteolytic enzymes on its surface to facilitate this process.
Hypnozoite
The dormant liver stage of P. vivax and P. ovale. The parasite remains in hepatocytes after the other liver-stage parasites have replicated and released their merozoites. Hypnozoites are the source of malaria relapses.
Gametocyte
The male and female sexual stages of the malaria parasite. Formed in the red blood cells, it remains dormant unless taken up by a mosquito, in which it forms gametes, which fuse to form the ookinete. episodes, mainly targeting the asexual blood stages of P. falciparum. However, an arsenal of drugs will also be needed to tackle emerging drug resistance, block the transmission of the parasite to other persons by the mosquito vector and, in the case of Plasmodium vivax infection, target the dormant liver stage of the parasite.
In this Review, we examine the currently available antimalarial drugs, their limitations and the need for new drug classes with improved product profiles. We also consider some of the challenges that are faced in the development and delivery of new medicines in a costeffective and timely fashion, and the solutions required to overcome them.
The challenges of the Plasmodium species There are four main species of the malaria parasite that are known to infect humans. P. falciparum is responsible for the majority of the malaria-linked deaths in sub-Saharan Africa and is therefore currently the most important target. P. vivax causes as much as 25-40% of the global malaria burden 6 , particularly in South and Southeast Asia, and Central and South America. It does not normally progress to cerebral malaria, and has traditionally been labelled benign. However, P. vivax causes a greater increase in the host inflammatory response than P. falciparum at equivalent parasitaemia 7 . Also, it is probable that mortality from P. vivax is under-reported, as recent analyses in Papua (Indonesia) have shown similar mortality figures in children infected with P. vivax to those infected with P. falciparum 8 . The other two main species that are known to infect humans are Plasmodium ovale and Plasmodium malariae. Currently, these are diagnosed by microscopy and represent a small percentage of infections. In addition, some human malaria can be caused by the primate malaria parasite, Plasmodium knowlesi, but it has not been established whether human-mosquitohuman transmission can occur.
Drugs that are active on the asexual blood stages of P. falciparum, such as the artemisinin-based combination therapies (ACTs), are assumed to be fully active against the other species. Mixed infections of P. falciparum and P. vivax are rarely reported, but PCR detection methods have shown that these can be as high as 30% of all Plasmodium infections 9 . Diagnosis based on PCR analysis will undoubtedly lead to a re-evaluation of the presence of mixed infections.
From a treatment and eradication perspective, there are three key differences between the species. The first difference occurs in the liver. Following infection by a mosquito (FIG. 1) , P. falciparum and P. malariae rapidly progress through the hepatocytes, undergoing asexual division with the release of large numbers of merozoites into the host bloodstream. For P. vivax and P. ovale, some of the parasites in the hepatocytes become dormant hypnozoites 10 . These forms can be reactivated after periods which vary depending on the species and the host, and can be as short as 3 weeks or as long as several years. Unless the hypnozoites are eliminated, the disease caused by these species will continue to relapse. As P. vivax transmission is rarely intense, activation of hypnozoites is thought to be an important contributor to disease frequency.
The second difference between the species is in the time taken for the parasite to replicate in the host. The time between febrile paroxysms varies from ~48 hours f or P. falciparum and P. vivax to 72 hours for the more benign P. malariae. There has been a recent interest in P. knowlesi 11 , as PCR methods show that it is often misdiagnosed as P. malariae infection, which is usually uncomplicated and has low parasitaemia. However, P. knowlesi replicates every 24 hours, and so is potentially life threatening if not treated properly 12 . In this case, developing a therapy with a rapid onset of action will be crucial.
The third difference between the species is the timing of the appearance of gametocytes in the bloodstream 13 . In P. falciparum infection, the gametocytes do not appear until several days after the initial parasitaemia and fever whereas, in P. vivax infection, they appear concurrently or even before asexual parasites. An ideal treatment for blood stages of P. vivax must be able to kill existing gametocytes, rather than simply prevent them from differentiating.
Currently available antimalarials
The first widely used antimalarial drug was quinine, a natural product extracted from the bark of the tree Cinchona calisaya. Synthetic derivatives of quinine (FIG. 2) , such as the 8-aminoquinoline primaquine and the 4-aminoquinoline chloroquine, can be traced back to the pioneering work of Ehrlich on methylene blue in the late nineteenth century. These drugs cause parasite death by blocking the polymerization of the toxic byproduct of haemoglobin degradation, haem, into insoluble and non-toxic pigment granules, resulting in cell lysis and parasite cell autodigestion 14 .
Rationally designed therapies have followed this antimetabolite approach. For example, malaria parasites are unable to salvage folate, but need this cofactor to synthesize tetrahydrofolate for methylation reactions. Inhibitors of dihydropteroate synthase (by sulphonamides such as sulphadoxine) and dihydrofolate reductase (by 2,4-diaminopyrimidines such as pyrimethamine) are potent antimalarial drugs, especially when administered in combination. For most of the second half of the twentieth century, control of acute uncomplicated malaria caused by all four species of Plasmodium involved the use of chloroquine for first-line treatment and a combination of sulphadoxine and pyrimethamine as secondline treatment.
In all cases, resistance to these drugs has emerged. Resistance to drugs such as sulphadoxine-pyrimethamine, for which there are specific enzyme targets, arose more rapidly than to chloroquine, for which the target is haem polymerization. Also, for reasons that are unclear, chloroquine resistance arose more rapidly in P. falciparum than in P. vivax. The initial strategy to address this was to modify the molecular structure of the existing drugs. Synthesis of pyrimethamine-like drugs did not result in an active replacement. However, the synthesis of chloroquine-like drugs led to the discovery of lumefantrine, piperaquine and pyronaridine in China, and amodiaquine, mefloquine and halofantrine in the United States. All of these molecules were active against chloroquine-resistant strains of P. falciparum. 
Oocyst

Fever clearance time
The time taken for body temperature to return to normal levels after the first dose of an antimalarial has been given.
Drugs targeting P. falciparum.
The key event that led to the current era of treatment for P. falciparum infection can be dated back to the discovery of the sesquiter pene lactone artemisinin (known as Qing hao su) in 1972 by Chinese scientists 15 . It is an endoperoxide-containing natural product isolated from the leaves of the sweet wormwood, Artemisia annua. More potent derivatives of artemisinin were subsequently developed, including dihydroartemisinin (DHA; the main active metabolite), artemether, artemotil and artesunate (FIG. 2) . Whereas both artemether and artemotil are insoluble, artesunate has good solubility and is therefore suitable for intravenous and oral administration. The new artemisinin derivatives were fully active against all existing drug-resistant strains of P. falciparum. Unlike other antimalarial drugs, the artemisinins rapidly kill all the blood stages of the parasite, resulting in the shortest fever clearances times of all antimalarials 16 . Furthermore, the artemisinins also kill gametocyte stages, thereby reducing transmission. The risk of drug resistance can be reduced by combination therapy (BOx 1). The frequency of resistance to P. falciparum is estimated at 1 in 10 10 parasites, and there is a parasite burden of ~10 12 in severe malaria. Combining two medicines with different mechanisms of action lowers the probability that a resistant parasite will emerge 17 . In 2006, the WHO produced new treatment guidelines for uncomplicated P. falciparum malaria, advising that the treatment of choice should be a combination of two or more antimalarials with different mechanisms of action 18 . The gold standard has become fixed-dose ACTs, with both drugs in the same tablet. Anopheles mosquito (step 1). They are rapidly taken up into the liver, where they pass through the Kupffer cells and infect the hepatocytes (step 2). In all species of Plasmodium, these parasites develop to form exo-erythrocytic schizonts from which several thousand merozoites develop (step 3). In Plasmodium vivax and Plasmodium ovale only, a proportion of the liver-stage parasites remain in the hepatocytes as a dormant form, or hypnozoite 7 (step 4). This stage of the parasite can remain dormant for a few weeks or up to several years. These species of parasite can therefore start a cycle of asexual reproduction without the need for further mosquito bites, which is why P. vivax infection is also referred to as relapsing malaria. When the liver cells rupture, the merozoites are released into the bloodstream where they rapidly invade the red blood cells (step 5). The intra-erythrocytic parasites replicate synchronously, leading to the classical cycle of fever that is observed clinically (step 6). Some merozoites infecting red blood cells develop into male and female gametocytes (step 7). In P. falciparum, these are formed in the later stages of infection. By contrast, in P. vivax, they are formed at the same time as the asexual stages. Gametocytes are taken up into the female mosquito gut during the blood meal (step 8). The male gametocytes are activated (ex-flagellation) and form gametes, which fuse with the female gametes to form diploid ookinetes (step 9). These ookinetes migrate to the midgut of the insect, pass through the gut wall and form the oocysts. Meiotic division occurs and sporozoites are formed (step 10), which then migrate to the salivary glands of the mosquito (step 11). The time taken for asexual parasites to no longer be detectable microscopically after the first dose of an antimalarial has been given.
Artemether-lumefantrine (Coartem; Novartis/Chinese Academy of Medical Military Sciences), the first such fixed-dose ACT, was launched in 2001. It has the advantage that lumefantrine had never been used as a monotherapy, and so there has been no opportunity for drug resistance to develop against it. Subsequently developed ACTs, containing amodiaquine, mefloquine, piperaquine and pyronaridine, do not have this advantage.
Drugs targeting P. vivax.
In contrast to P. falciparum malaria, P. vivax malaria is generally still treatable with chloroquine, which remains the WHO's recommendation for first-line treatment against this species. However, some areas in South and Southeast Asia now harbour chloroquine-resistant P. vivax parasites 15 . In these areas, the WHO recommends the use of an ACT. For P. vivax malaria, the particular challenge remains the prevention of relapse as patients who have had all blood stages of the parasite removed can still be re-infected by activation of the hypnozoite. Among the first generation of synthetic drugs for malaria was the 8-aminoquinoline pamaquine (FIG. 2) , which was introduced in 1926 (ReF. 19 ). It has antirelapse activity but causes haemolysis in patients who have a deficiency in the enzyme glucose 6-phosphate 1 dehydrogenase (G6PD), meaning that ideally it should not be prescribed without patient screening. This is a considerable problem in disease-endemic areas, where up to 20% of the patients might have this deficiency 20 . A second-generation molecule, primaquine, was initially used to treat those returning from the Korean war, in whom long-term relapses were common. It is now the anti-relapse drug of choice for P. vivax malaria. However, primaquine also causes haemolysis in G6PD-deficient patients and must be taken daily for 14 days to be effective; such compliance is unachievable in practice. A thirdgeneration 8-aminoquinoline, tafenoquine, which could be taken as a 2-3-day treatment course, is currently in clinical development 21 . The mechanism of action of the 8-aminoquinolines against hypnozoites and the mechanism of haemolysis are not known, but they might be similar. Primaquine metabolism includes the formation of a reactive quinone imine, and potentially a peroxy radical, which would be more toxic in the absence of G6PD as the cellular environment would be more oxidative.
Drugs targeting severe malaria. Severe malaria presents additional clinical challenges: patients are unconscious and need a rapidly acting intravenous or intramuscular medication. Traditionally quinine was used, but the rapid parasite clearance time (PCT) of artemisinin derivatives makes them clinically superior 22 . Developing new drugs for severe malaria requires large studies of up to 5,000 patients. Currently, the main challenge is to ensure a supply of drugs that are manufactured to international standards of good manufacturing practice (GMP). Not everyone has access to a health worker who can inject a drug, and so a rectal artesunate formulation has been developed as a prereferral treatment for use while the patient is rushed to the clinic 23 .
Prophylaxis. Prophylaxis for high-risk groups, particularly pregnant women and children, in countries in which malaria is endemic, was promoted in many African countries post-independence. In children under 5 years of age, this intervention has been shown to increase mean haemoglobin levels, reduce the frequency of clinical episodes and reduce overall mortality. The effects in pregnant women, particularly among those who are pregnant for the first time, include a significant increase in haemoglobin, a reduced prevalence of placental infection, a reduction in the frequency of prematurity and low birth weight, and therefore an increase in life expectancy of the newborn.
Difficulties in maintaining compliance, together with an impaired acquisition of natural immunity in young children, led to a re-formulation of the approach of giving antimalarials for prophylaxis to these two high-risk groups. Intermittent preventive treatment (IPT) aims to deliver antimalarial prophylaxis at defined intervals, mostly using contacts that already exist between the target population and the health services for delivery. A regimen of two or three doses of sulphadoxinepyrimethamine, chosen because of its long half-life, delivered during pregnancy has been shown to provide considerable benefit to both the mother and the foetus, and is currently implemented routinely as part of comprehensive malaria control strategies throughout most countries in which malaria is endemic. A similar approach is being developed for infants of up to 5 years of age. The medicine is administered during the routine vaccination contacts that are made during the first year of life, and there is strong evidence to suggest that the approach is safe and confers a considerable and costeffective health benefit 24 . IPT is likely to be most beneficial in areas of high parasite transmission, and its policy implications are currently being reviewed by the WHO. Although sulphadoxine-pyrimethamine retains substantial prophylactic efficacy, despite moderate to high levels of resistance to treatment, there is obviously concern that it may eventually lose its effectiveness. Many of the other antimalarial drugs developed so far also have long half-lives (that of mefloquine is 21 days, for example). Therefore, in addition to curing any existing parasitaemia, a single administration might prevent subsequent infections for several weeks. Clinically, a single course of treatment of artemether-lumefantrine or DHA-piperaquine protects 70% and 80% of patients, respectively, from re-infection over the following 6 weeks (M. Corsi, personal communications). The drug development challenge in both infants and pregnant women is to determine the correct dose. Not only are the pharmacokinetics different in these populations, but the drug exposure needed for prevention will be different from that required for cure.
Antimalarial medicines are used not only for treatment but also for prophylaxis in high-risk groups. Nonimmune travellers, to malaria-endemic areas are an important group. Of the antimalarial drugs that have been developed, only pyrimethamine, proguanil and atovaquone are known to have causal prophylactic activity, and prevent the infection from reaching the blood stage. All other chemoprophylactics work solely as blood schizonticides. The drug of choice is GSK's Malarone, a fixed combination of atovaquone-proguanil, which has causal prophylactic, blood schizonticidal and transmission-blocking activities 25 . It is relatively expensive compared with other antimalarials, owing to the difficulty in making atovaquone, and has to be administered daily. Mefloquine, which is less expensive and has a long half-life, provides good prophylaxis even when administered weekly, but it is associated with gastro intestinal and psychiatric side effects. It is a mixture of two diasteroisomers, and preclinical data suggest the psychiatric effects are due to the (-)-erythro diastereoisomer. Clinical studies are ongoing with the pure (+)-erythro diastereoisomer, to determine whether this has a better safety profile. Older drugs such as chloroquine, sulphadoxinepyrimethamine and biguanides (such as proguanil) have reduced efficacy in a number of areas owing to increasing resistance.
The future of ACTs There are currently five fixed-dose ACTs available (TABLe 1) . The development of a medicine with two active ingredients poses unique challenges. First, there is the need to select two active ingredients with different mechanisms of action that are therapeutically synergistic but do not adversely affect the uptake, distribution or safety of each other. The optimum dose for each ingredient needs to be confirmed in patients. Second, co-formulation is often a challenge, as the drugs must not interact with each other chemically. The final product has to be stable, preferably for 2-3 years with less than 5% degradation, under conditions of high temperature and relative humidity (30 ± 2°C and 65 ± 5% relative humidity) (details on the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use website; see Further information). With a cost limitation of $1 per treatment, formulation must not substantially increase the expense. Third, medicines may have to be dosed and formulated differently for small children and pregnant women.
One Achilles' heel of ACTs is that they rely on artemisinin derivatives, and are all susceptible to the same mechanism of drug resistance. Early warnings of resistance have come from the observed increased PCTs on the Thai-Cambodian border 26 . The mechanism of action of artemisinin involves activation of the endoperoxide moiety by Fe 2+ , which is liberated in the infected erythrocytes during haemoglobin digestion 27 . Specific molecular targets have been identified 27 , but such a reactive intermediate could attack many targets. Although small changes in the half-maximal inhibitory concentration (IC 50 ) of artemisinin-based drugs have been reported 28 , no artemisinin-resistant isolate has been characterized. Potential mechanisms for resistance include mutations in genes encoding drug efflux pumps (as were seen for the 4-aminoquinolines) or mechanisms that alter the concentration of free Fe 2+ (required for endoperoxide activation). Several research groups have developed synthetic artemisinin analogues, based on the endoperoxide motif, but with diverse structures (five-or six-membered rings 29 and with three or four oxygen moieties 30 ) (FIG. 2) . Five are in the late stages of development, including OZ277/ RBx11160 (ReF. 31 ), OZ439, CDRI97/78, PA1103/ SAR114262 and a semi-synthetic molecule, artemisone. Will these share a common resistance pathway with artemisinin? This would be unlikely if resistance is due to an efflux pump, given the diversity of chemical structures of the compounds. However, if resistance arises from controlled destruction of the endoperoxide, a considerable portion of the drug development pipeline could be at risk. These compounds are currently being tested against clinical isolates to better understand this situation.
If all endoperoxide compounds eventually become compromised by resistance, how will we treat patients in the medium term? Malaria therapy could revert to more traditional antibiotics, some of which are in Phase II and Phase III clinical trials for this indication (FIG. 3) . The most advanced product is the combination of azithromycin and chloroquine, which is currently in Phase III clinical development for IPT during pregnancy. Azithromycin is only moderately effective against malaria parasites as a monotherapy, but its activity is enhanced in the presence of chloroquine 32 . Interestingly, the antibiotic reverses the clinically observed chloroquine-resistance phenotype, by a mechanism that is not yet known 33 . The fact that this is the only combination in Phase III trials that does not contain an endoperoxide underlines the importance of representing a wide range of molecular targets in a drug discovery portfolio. The alternative line of defence against artemisinin resistance would be atovaquone-proguanil. However, the ease with which resistance to this combination develops in the laboratory, combined with the cost, means that from a public-health perspective it would be advisable to save this medicine as a last resort. Antimalarial target product profiles Successful drug discovery involves starting with a clear idea of what the final product should ideally look like and being able to describe this in a target product profile (TPP). In the case of drug combinations, the TPP summarizes the properties of the combination medicine; a single molecule does not have to tick all the boxes. TABLe 2 summarizes the TPPs for antimalarial drugs.
As we consider our current efforts to control malaria and the goal of eradication, it is apparent that new oral antimalarial products for the treatment and prophylaxis of malaria ideally should have four important properties. First, they should be able to treat existing disease -that is, they should have activity against the blood parasites of the four key species that cause malaria in humans, including organisms that are resistant to existing therapies. Second, they should kill the hypnozoites of P. vivax and P. ovale and prevent relapse. Third, they should kill gametocytes to prevent re-infection of mosquitoes and subsequent transmission to other people. Fourth, they should have causal prophylactic activity, preventing initial infection following a mosquito bite by killing the sporozoites and exo-erythrocytic schizonts. It is unlikely that an individual molecule will have all of these attributes, and considerations of resistance generation suggest that a drug combination strategy is preferable.
An appropriate combination of drugs, formulated into a fixed-dose combination product, should be sufficient. In addition, if artemisinin resistance spreads, there will also be a need for a new fast-acting blood schizonticide that can be administered as an intramuscular or intravenous injection for severe malaria.
One of the most important aspects to consider at an early stage is the cost of the product: in disease-endemic countries, patients can often only afford $0.10 per treatment regimen. The target ex-factory price for new treatments is currently considered to be $1, which means that components must be relatively potent or very cheap. The Global Fund for HIv, Tuberculosis and Malaria is launching the AMFm, which should both subsidise the purchase of drugs and manage the price increases along the supply chain, allowing this price gap to be bridged in both the public and private sectors.
Another important aspect in malaria drug development is patient compliance. Current treatments for uncomplicated malaria require 3 days of dosing. As with antibiotics in the West, there is a risk that patients will not finish the course of treatment, as fever is cleared early in treatment. With hypnozoites the challenge is even greater: currently the treatment is 14 days of primaquine, with no symptomatic effect on patients. Short courses of treatments that can be directly monitored will be advantageous in an eradication programme.
Safety is also a crucial issue for new antimalarials. The current medicines have a good safety profile, with serious adverse events observed at a frequency lower than one patient in a thousand. The main reason for the high mortality associated with malaria is a lack of access to therapy in the short term and the threat of resistance in the long term. An important consideration is that the new medicines will be used by millions of patients in malaria-endemic countries where safety reporting is not well developed. It is therefore doubly important that the development of a new antimalarial product should follow the same guidelines as any therapy intended for use in Europe, the United States or Japan. The ICH guidelines ensure that all the work reported meets a certain standard, particularly with regard to the efficacy, safety and stability of the drug. A key standard that is expected by the regulatory authorities in these areas is that an adequate number of patients, usually 2,000-3,000 in total, have been given the medicine during the clinical development programme. In addition, the development programme should effectively represent all the age ranges and patient types affected by the disease. Such studies should prevent the approval of medicines that cause high levels of serious adverse events and give a preliminary idea of the degree and frequency of nonlife-threatening side effects. Further Phase Iv trials, which examine the seriousness of adverse events, as well as post-marketing surveillance, will enable an accurate assessment of the risks and benefits of a new medicine. This issue is particularly important in the case of malaria, as national malaria control programmes aim to change the status of such medicines from prescriptiononly to over the counter, to facilitate access to the whole population. Another important issue to consider when developing antimalarial drugs is the quality of the medicine itself. Counterfeits of branded medicines, which often contain no active ingredients 34 and medicines that contain less than the required active ingredient (owing to inappropriate standards of manufacture, formulation, packaging and stability), result in further morbidity and an increased risk of the development of resistance. Therefore, stringent international standards of GMP, set by regulatory authorities or the WHO, need to be followed. In addition, programmes for access to medicines must ensure that the medicines that are most readily available are those of the highest quality, with constant surveillance for counterfeits and local enforcement of standards in disease-endemic countries.
The arrival of new technologies
In malaria drug discovery, two major technological breakthroughs in the past 7 years have greatly enhanced our discovery efficiency. First, the sequencing of the whole genomes of P. falciparum 35 and P. vivax 36 , which has been important in identifying the full range of potential drug targets. Moreover, it has provided the basis for comparisons between the gene expression patterns at different stages of the parasite lifecycle and between different parasite species. This data set provides the ability to search for target classes that have not been pursued before in drug discovery 37 . It is still possible to prioritize novel targets based on the likelihood of finding a small-molecule inhibitor 38 and on their similarity to targets for which a drug has already been found. This opens up the possibility of 'orthologue searching': compounds in a company's database can be selected from medicinal-chemistry programmes that are directed against a human target for which there is a close relative in the parasite. A small collection of compounds, including structurally related, active and inactive compounds against the human target, can then be tested against the parasite enzyme. This has been successful with other pathogens, with hit rates as high as 10-25%, and can lead to the development of compounds that are selective for the parasite target 39 .
The second key development is high-content screening: the ability to study the viability of the parasite in 384-and 1,536-well formats 40 . This means that large compound collections can be rapidly screened, with throughputs of 100,000 per month possible even in academic centres (v. Avery, personal communications). This has changed the dynamics of interactions between researchers in industry and academia, as compound collections can be screened blind at a cost of less than $1 per compound. In the assays to determine the viability of P. falciparum in erythrocytes, the hit rate is often as high as 0.5% of compounds showing activity at less than 1 μM. This gives several chemical series to work on: over 10,000 distinct hits from a major pharmaceutical collection can be prioritized at an early stage. Early prioritization can be based on potency against Plasmodium spp., half-life, lack of activity against human cell lines and a potentially low cost of goods. Identifying the molecular target is not 
Reticulocyte
An immature red blood cell.
simple but the aim should be to identify the molecular mechanism at the stage when a clinical candidate is selected.
The success of high-content screening in finding new chemotypes with activity against the erythrocytic stages suggests that this could be applied to the other stages of the parasite lifecycle. These assays exist for gametocytes and liver stages for both P. falciparum and P. vivax, with the exception of the hypnozoite. The challenge is to automate these screens and make them suitable for 384-well assays. For the hypnozoite stages of P. vivax, the problem is more complex 41 as infective P. vivax sporozoites are needed, and so access to mosquito breeding facilities is required. To infect the mosquitoes requires access to blood from patients or experimentally-infected primates. New technologies for cryopreservation of sporozoites could facilitate this process 42 . The cell culture challenges are also more complex for this species, as P. vivax requires reticulocytes for culture. The hepatocytes used in culture represent a further challenge: cell lines are available but they have low infection rates 43 . Most work is still focused on primary human hepatocytes or infecting primate hepatocytes with the related species Plasmodium cynomolgi. The recent spotlight on eradication has served to increase the amount of funding for this area, and there are some initial results suggesting a cell-based assay for hypnozoites might be possible.
Having consistent tests for all of the stages of the parasite life cycle will be an important step forward in the agenda to find new medicines. A short-term objective would be to test all the molecules that are currently in the malaria drug development pipeline in the available cell assays for all the key stages of the parasite lifecycle discussed above, and generate malaria 'life cycle fingerprints' for each molecule. This will enable side by side comparison of molecules at a reasonably early stage, and could be crucial for entering the right medicines into the appropriate clinical assays. The key challenges in earlystage discovery brought by the eradication agenda are summarized in The malaria research pipeline Over 90% of current malaria drug discovery projects are targeting the asexual blood stages of P. falciparum. Those which are close to clinical development have been recently reviewed 44 . The first group are those which aim to improve on drugs that have validated activity in human disease (traditionally known as 'fast followers'). Strategies include improving inhibitors of dihydrofolate reductase to develop drugs that are active against resistant strains 45 , and developing new inhibitors of mitochondrial electron transport, which are active against atovaquone-resistant parasites with mutations in cytochrome bc1 (ReF. 46) . Here, the TPP is reasonably simple, and the key advantage of a new-generation inhibitor will be action against resistant strains of the parasite. Improvements in the potency of 4-aminoquinolines or amino-alcohols is another potential approach. In this case, there is the opportunity to make a radical change in the way the drug is presented (for example, combining a 4-aminoquinoline with an endoperoxide 29 or combining an antimalarial with a resistance blocker 47 ). However, with the prospect of 5 fixed-dose ACTs being available to patients over the next 2 years, any new 4-aminoquinoline-containing compound must show a substantial benefit in terms of cost or safety. Another strategy is to develop drugs on the basis of newly defined molecular targets for which there are supporting data that an inhibitor will have an effect on the parasite, but as yet no clinical validation (TABLe 4) . The project in question is usually supported by strong in vivo data, such as the finding that specific gene knockouts prevent the generation of viable cell lines in P. berghei. Although such validation is useful, confirmation is based on a negative result and there are substantial differences between P. berghei and P. falciparum 36 . For many of these targets, medicinal chemistry is aided by high-resolution structural information. Pathways such as nucleoside biosynthesis have been highlighted by genome sequence analy sis 41 , leading to the identification of three potential drug targets. Dihydroorotate dehydrogenase (DHODH) has been targeted, as the parasite and mammalian forms differ considerably. Screening against DHODH has yielded potent and selective compounds that can now be optimized with the availability of high-resolution structural data of the enzyme-ligand complex 48, 49 . The power of the rational design approach has also been underlined by the design of inhibitors of adenosine deaminase based on detailed electronic calculations of the reaction transition state 50 . Also, inhibitors designed to be active against the transition state of purine nucleoside phosphorylase have been shown to be active against P. falciparum 51, 52 . Some of these compounds are ready for testing in humans and have been shown to be safe, and so it should be possible to rapidly evaluate the target in human malaria.
Apicoplast
An organelle that is present in malaria parasites and is thought to be a relic of the chloroplast. It contains DNA which codes for ~30 plant-like proteins and bacteria-like ribosomes. A further 500 nuclear-encoded proteins of unknown phylogenetic origin are predicted to be targeted to this organelle.
A potential set of key pathways to be used as drug targets occur in the apicoplast in Plasmodium spp. This organelle is not found in the human host, and contains metabolic pathways and enzymes that are similar to those seen in plant choloroplasts 53 . These pathways should offer targets that have a high degree of parasite selectivity. The most extensively studied is the 1-deoxy-d-xylulose 5-phosphate pathway for isoprenoid biosynthesis, which is the target of fosmidomycin, now in Phase II clinical trials in combination with clindamycin or azithromycin. In addition, the apicoplast has unique fatty-acid biosynthesis pathways 54 , suggesting that other parasite targets that are inhibited by herbicides should be considered. Unfortunately, inhibiting these pathways leads to long PCTs, with parasite death delayed until the next round of replication.
Another approach to drug discovery is to use the expertise on target families that have already been successfully targeted in other therapeutic areas -for example, kinases 55 and histone deacetylases 56 . The challenge is to identify molecules that can be sufficiently discriminated from the equivalent host targets to ensure safety. In the case of protease targets, such as the cysteine proteases, falcipain 57 and the serine protease PfSUB1 (ReF. 58 ), inhibitors were difficult to develop as drug candidates because of selectivity issues.
Most of these approaches target the erythrocyte stages of P. falciparum. However, if the drugs could be delivered by an intramuscular or intravenous route, rather than orally, and were fast-acting, they could also be developed for severe malaria, as has been shown for a specific choline channel blocker, albitiazolium bromide (known as TE3 and SAR97276; Centre Nationale de la Recherche Scientifique/Sanofi-Aventis), which is now in Phase II clinical trials 59 . Developing compounds that are active against gametocytes, sporozoites, exo-erythrocytic liver schizonts and hypnozoites is considerably more challenging, as a reliable cellular model is needed to define whether key metabolic pathways, such as mitochondrial respiration or nucleoside biosynthesis, are crucial for the reactivation of the hypnozoite. The lack of information in this area underlines how neglected the research into P. vivax hypnozoites has been.
Public-private partnerships
In the past decade, there has been a fundamental shift in the way that new medicines are developed for neglected disease. Although the global antimalarial drug market is huge in terms of unmet medical need, it is small in terms of profit. Owing to the low price that can be charged for malaria medicines in disease-endemic countries, it is not possible to obtain a financial return on R&D investment from these drugs. To bridge this gap a new model has been developed, by which academia and the biotechnology and pharmaceutical industry can collaborate to discover, develop and deliver new medicines. The new Medicines for Malaria venture (MMv) was established in 1999 as a public-private partnership (PPP), which provides much of the necessary finance, without expectation of repayment, so that emerging new products can be priced solely on the basis of manufacturing costs. Working in concert with another PPP -the Drugs for Neglected Disease initiative (DNDi) -and using financial resources provided by the Bill and Melinda Gates Foundation, other private foundations and a number of governments, the MMv with the help of its partners has established a large portfolio of antimalarial drugs. By sharing knowledge and best practice across the industry, the discovery and development of the next generation of medicines will be greatly accelerated. 
Conclusions
Spurred on by the global spread of resistance to the current standard antimalarial drugs, such as chloroquine and sulphadoxine-pyrimethamine, the past 10 years have seen a considerable expansion in the research and development of new medicines to maintain and improve the clinical control of malaria. Now, with the re-introduction of a malaria eradication agenda, the next 10 years are set to be even more demanding. In the short term, there should be a group of new ACTs available for use. The challenge will be to better understand how to deploy these for treatment and prophylaxis in the populations that are currently most at risk -young children and pregnant women. For the medium-term treatment of malaria, there is a strong clinical pipeline of new medicines that could deliver additional ACTs if these are required, a new, shorter-course co-packaged radical cure for P. vivax malaria, a GMP parenteral formulation of artesunate for severe malaria to replace intravenous quinine, and the first of a series of innovative non-artemisinin-based combination therapies to deal with ACT resistance. For the long-term treatment and eventual eradication of malaria, there are further challenges -in particular, the urgent need for medicines to target the dormant hypnozoite stage of P. vivax, and for new products which will block the transmission of malaria by killing the gametocytes and inactivating sporozoites and exo-erythrocytic schizonts. At the same time, we must keep a watchful eye on the emergence of resistance and develop an understanding of its potential impact on priority needs for new medicines.
Radical cure
The elimination from patients infected with P. vivax or P. ovale of all parasites, including the dormant liver hypnozoites. Unless this is done, patients will subsequently relapse.
